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Essentials
 The factor IX (FIX) cross-reactive material (CRM) might modulate infused FIX distribution
 The contribution of F9 genotypes on infused FIX pharmacokinetics was investigated
  FIX activation site (R191/226) variants (HB patients n>300) express medium/high CRM levels 










This article is protected by copyright. All rights reserved
Summary
Background: Circulating dysfunctional factor IX (FIX) might modulate distribution of infused 
FIX in haemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, 
>300 patients) are associated with variable FIX activity and antigen (FIXag) levels. 
Objectives: To investigate i) expression of a complete panel of missense mutations at FIX 
activation sites and ii) contribution of F9 genotypes on the FIX pharmacokinetics (PK). 
Methods: FIXag and activity assays in plasma and after recombinant expression of FIX variants.  
Analysis of infused FIX PK parameters in patients (n=30), mostly enrolled in the F9 Genotype 
and PK HB Italian Study (GePKHIS; EudraCT ID2017-003902-42).
Results: The variable FIXag amounts and good relation between biosynthesis and activity of 
multiple R191 variants result in graded moderate-to-mild severity of the R191C>L>P>H 
substitutions. Recombinant expression may predict the absence in the HB mutation database of the 
benign R191Q/W/K and R226K substitutions. Equivalent changes at R191/R226 produced higher 
FIXag levels for R226Q/W/P substitutions, as also observed in p.R226W female carrier plasma.
PK analysis in patients suggested that infused FIX Alpha distribution and Beta elimination phases 
positively correlated with endogenous FIXag levels. Mean residence time was particularly 
prolonged (79.4 hrs, 95% CI 44.3-114.5) in patients (n=7) with the R191/R226 substitutions, 
which in regression analysis were independent predictors (β coefficient 0.699, p=0.004) of Beta 
half-life, potentially prolonged by the increasing over time ratio between endogenous and infused 
FIX.
Conclusions: FIXag levels and specific features of the dysfunctional R191/R226 variants may 
exert pleiotropic effects both on HB patients’ phenotypes and substitutive treatment.
Keywords










This article is protected by copyright. All rights reserved
INTRODUCTION 
The activation of coagulation factor IX (FIX) has a key role in the coagulation cascade, either via 
activated factor VII (FVIIa) in complex with tissue factor (TF) or via activated factor XI (FXIa) 
[1]. Full activation is achieved after cleavage at two highly conserved activation sites [2,3], which 
results in the release of the activation peptide [4–7]. More than 300 haemophilia B (HB) patients 
with recurrent F9 mutations affecting the R191 or R226 residues, encoded by CpG-containing 
codons [8], have been reported (EAHAD FIX variant Database, https://f9-db.eahad.org/) [9]. 
Seminal studies have indicated that single cleavage at R191 does not produce catalytic activity but 
converts FIX zymogen into a factor VIII (FVIII)-binding enzyme [10,11], whereas single cleavage 
at R226 develops catalytic activity but results in suboptimal binding to the FVIII light chain 
[11,12]. Accordingly, missense mutations at these positions are associated in HB patients with 
moderate/mild (R191) [13–21] or severe (R226, HBm mutation subclass) [14,22–28] FIX 
deficiency. Failure in the production of activated FIX (FIXa) [14,24,29] has been modelled in HB 
mice (R226W) [30]. 
Based on these information, we focused on F9 mutations affecting the FIX activation sites by 
systematic recombinant expression of natural and designed variants to interpret HB phenotypes, 
both residual activity and antigen levels, associated to virtually “all” amino acid substitutions. 
Previous results suggested that activation peptide sequences act as plasma retention signals, as 
observed for human FVII added with the FIX activation peptide, which prolonged 4.3-fold its half-
life when tested after infusion in mice [31,32].
Concerning the distribution of FIX infused in HB patients, it has been hypothesized that the 
presence of  cross-reactive material (CRM+), namely the circulating FIX antigen (FIXag) with 
reduced or null activity,  might partially improve the in vivo recovery of FIX infused in HB 
patients [33]. Differently, in HB mice, the presence of dysfunctional endogenous FIX caused by 
the human R379Q variant [34] may decrease replacement efficacy [35]. Based on these 
observations, it has been proposed that prophylaxis regimens in HB patients should consider the 
CRM status [36]. Since observations in patients and animal models may be explained by the 
dynamic equilibrium between plasma FIX and the extravascular protein bound to the 
subendothelial basement membrane [37–40], a two-compartment (2CP) pharmacokinetic (PK) 
model best describes the distribution of FIX infused in HB. We report the PK analysis of FIX 
infused in severe/moderate HB patients, enrolled in the frame of the F9 Genotype and PK 
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Plasma samples from HB patients (n=30), mostly enrolled in the GePKHIS study, and in addition 
three related female carriers of the p.R226W variant, were collected and processed at the local 
haemophilia centres belonging to the Italian Association of Haemophilia Centres (AICE). The 
study was approved by the coordinator centre (Ferrara, code ACTB02BD04), as well as by each 
local ethics committee, and was registered in the EudraCT database (ID 2017-003902-42). The 
study was carried out in accordance with the Declaration of Helsinki principles, and written 
informed consent was obtained.
Study design 
The protocol was approved for severe/moderate HB patients (Supporting Table 1) undergoing on-
demand or prophylactic treatment with Nonacog Alfa (Pfizer, New York, USA).
Inclusion criteria to participate in the study were: severe or moderately severe HB (FIX activity ≤ 
3 IU/dL); no bleeds in the last week before assessment of PK; on-demand or on-prophylaxis 
treatment with Nonacog Alfa for >150 exposure days. 
Exclusion criteria were: any kind of bleeding in the last week before the PK; severe hepatic 
disease; ongoing HIV treatment (HAART); history of anti-FIX inhibitors; previous treatments 
with extended half-life FIX concentrates. The PK study was not conducted in the HB patient with 
the p.R191H variant, associated with a mild HB phenotype (FIX coagulant activity >5%; see 
Supporting Table 1). For this patient, only the basal activity and antigen levels were determined.
Nomenclature
All amino acids are numbered according to the Human Genome Variation Society (HGVS) 
nomenclature [41].
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The F9 genotypes of HB patients undergoing PK (Supporting Table 1) were characterized as 
described [20]. Causative mutations were classified as missense (n=16, patients n=21), nonsense 
(n=4), splicing (n=2) and deletion (n=2) variants. 
Expression of recombinant variants 
Recombinant FIX (rFIX) variants were created by site-directed mutagenesis of F9 cDNA 
(reference sequences: NM_000133.4, NP_000124.1) cloned in the pCDNA3 vector [42]. 
Oligonucleotides are listed in Supporting Table 2. All plasmids have been validated by 
sequencing. Nonsense variants have been produced in previous studies [43,44]. 
Expression studies were carried out through transient transfection of human embryonic kidney 293 
(HEK293) cells in the presence of 5 μg/mL vitamin K (Konakion, 10 mg/mL), essentially as 
described [42]. Briefly, cells were seeded in 12-well culture plates and transfected in serum-free 
medium (Opti-MEM, Gibco, Life Technologies, USA) with the Lipofectamine 2000 reagent (Life 
Technologies) with a ratio DNA (µg):Lipofectamine (µl) of 1:1 (2 µg DNA: 2µl Lipofectamine) 
and media were collected 48 hours (hrs) post-transfection.
Evaluation of protein and activity of rFIX variants
FIXag levels were evaluated by polyclonal anti-human FIX ELISA (FIX-EIA, Affinity 
Biologicals, Canada) [43,44] to minimize the effects of mutations on detection of FIX epitopes. 
Known concentrations of purified rFIX were used as reference.
Protein forms derived from FXIa-dependent activation [45] of rFIX variants were evaluated 
through Western blotting analysis with polyclonal goat anti-human FIX (APGAFIX; Affinity 
Biologicals) and anti-goat horseradish peroxidase-conjugated (A50-101P; Bethyl Laboratories, 
Montgomery, TX) antibodies. Blotting images were acquired on the ChemiDoc instrument and 
analyzed by the Image Laboratory Software version 4.0 (Bio-Rad, USA).
Activity of rFIX variants in media was evaluated through a commercially available chromogenic 
assay exploiting an optimized FXIa concentration as per manufacturer instructions (Biophen; 
Aniara Diagnostica, West Chester, USA) [43]. Reaction aliquots were collected for Western 
blotting analysis. Serial dilutions of wild-type rFIX (rFIX-WT, mean concentration 485±51.5 
ng/ml), expressed in the same experimental conditions in parallel to rFIX variants, were used as 
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Evaluation of FIX protein and activity in plasma 
Serial dilutions of pooled normal plasma (PNP; Hyphen BioMed, France) were used as reference 
for analysis through  polyclonal anti-human FIX ELISA (Affinity Biologicals) [43,44] of FIXag 
levels in plasma from HB patients. Activity of infused/baseline FIX was measured by one-stage 
clotting method [46].
PK analysis
Each patient received a single-dose (40±5 IU/kg) of Nonacog Alfa. Plasma samples were collected 
before infusion and at 1-3-9-24-48-72 hrs post-infusion.
PK parameters were obtained through the 2CP model analysis (WinNonlin 7.0,  USA) [46–48], 
with the best fitting evaluated through the Sum of Squared Residuals (SSR) [49] and the 
Coefficient of Correlation between observed and predicted FIX concentration/time. The FIX/time 
concentrations  were corrected according to the Björkman formula [50] or by basal level 
subtraction, as appropriate. 
Specific primary (K 1-2, K 2-1 and V1) and secondary (Alpha HL, Beta HL, Clearance, CLD2, 
Cmax, MRT, V2, Vss and AUC) PK parameters, including in vivo recovery (U/dL per IU FIX 
concentrate/kg body weight infused) were evaluated  [46,51,52].
Statistical analysis
Statistical analyses were performed using IBM® SPSS® Statistics (version 23.0; IBM Corp., 
USA). Variables were reported as means with 95% confidence interval (CI). For skewed variables, 
the analysis was conducted with logarithmically transformed values. Two-tailed Pearson 
correlations were performed to determine the association between PK parameters and FIXag (%). 
F9 mutation type-related differences in PK parameters were analysed by t-test. In linear regression 
analysis, the contribution to PK parameters of FIXag levels and F9 mutation types was evaluated. 
Results
R191/R226 substitutions, plasma and recombinant phenotypes 
To compare expression levels of protein variants with amino acid substitutions at FIX activation 
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patients’ plasma, collected in the frame of the GePKHIS study, ii) inspection of the international 
database (https://f9-db.eahad.org/), and iii) systematic expression of rFIX variants harbouring 
natural or designed changes.
In HB patients (Figure 1A), the R191H/C substitutions result in reduced plasma FIX activity 
(Figure 2A, left panel) and normal (R191H) or moderately reduced (R191C) FIXag (Figure 2A, 
right panel) levels. The potential effects of the unpaired cysteine in the 191C FIX was explored by 
Western blotting analysis of plasma and conditioned medium performed in reducing/non-reducing 
conditions. Data did not support the presence of high molecular weight molecules produced by 
disulfide bond of the 191C variant, either circulating in plasma or after secretion in medium 
(Supporting Figure 1). The devoid-of-function R226Q/W variants showed normal or increased 
antigen levels (Figure 2A, right panel). The increased plasma levels associated to the R226 
substitutions is supported by data in HB patients and recombinant expression. Among the 60 
patients affected by the R226Q and reported in the database, eight have been characterized for the 
FIXag, with mean levels >100%. Patients (n=43) affected by the R226W change display (10 
patients evaluated) variable FIXag levels (range 130-50%, mean 84%). Among the GePKHIS 
patients bearing these substitutions, FIXag was >100%.
In expression studies, equivalent substitutions (R191/R226 to Q/W/P/L) (Figure 2B) caused 
significantly different effects at position R191 and R226, and were compatible with normal or 
increased secretion in media of the 226 variants as compared with near normal or reduced levels of 
the 191 variants. As an additional control for catalytically inert serine proteases we also expressed 
the S411P variant (chymotrypsin numbering S195), which also gave rise to high FIXag values.
Mutations affecting residues adjacent to R191 (A192P) and to R226 (V227F, V228L/F/A/G, 
Supporting Figure 2) are responsible for noticeable FIXag levels (70-130%), and for residual 
activity (2-20%) of most variants [17,27,53–55]. Inspection of the exome sequencing database 
GnomAD (https://gnomad.broadinstitute.org/) revealed the presence of 12 subjects carrying the 
conservative V227I change (rs137852242), suggesting a rare polymorphism (Supporting Figure 
2).
In expression studies we also designed and expressed rFIX control variants bearing a “classic” 
alanine change (R226A), or amino acid changes conferring negative (R226D/E) or positive 
(R226K) charge. Comparison between the natural (Q/W/P/L) and the designed (A/D/E, 
Supporting Figure 3) R226 variants in FXIa-dependent activation experiments (Figure 2C, left 
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peptide. Differently, the designed R226K variant, as expected for the conservative R-to-K amino 
acid change, displayed an activation pattern similar to that of rFIX-WT (Figure 2C, left panel), and 
reached an activity and activity/antigen ratio above 50% and 0.5, respectively (Figure 2C, right 
panel). 
To provide insights on the activity features of the R191C/L/P/H variants, the relation between 
FIXag  and activity was investigated by comparing findings in plasma and recombinant systems 
(Figure 2D), which showed a very good relation only for plasma values (r2=0.987). The normal 
FIXag levels for the r191L correspond to FIXag reduced to half in plasma, which suggests a FIX 
molecule with increased clearance  in vivo. The relation between activity and activity/antigen 
ratio, which magnifies the functional properties of the multiple natural and designed R191 
variants, was very good either excluding (r2=0.69; Figure 2E) or including (r2=0.98; Figure 2E, 
inset) the R191K variant, characterized by the highest activity and antigen values. The slope 
clearly indicated that the clinically relevant FIX deficiencies produced by the R191C/L 
substitutions (Figure 1A) are based on different functional properties. Conversely, the mild 
phenotype associated with the R191H deficiency is based on high secretion levels but modest 
catalytic properties.
Overall, comparison of in vivo and recombinant results of substitutions at activation sites provided 
a gradient of residual activity (R191) and antigen (both R191 and R226) values. The recombinant 
expression permits to extrapolate information that are not available in patients but help 
interpreting findings in patients.
Plasma FIX activity and antigen levels in female carriers of the p.R226W variant
We investigated plasma FIX activity and antigen levels in related female carriers [56,57] (n=3) of 
the p.R226W variant (Figure 3), to explore its potential influence on the proportion of the WT FIX 
and the inactive FIX variant circulating in plasma. The mean FIXag levels were higher 
(153.4±18.6%), than the mean FIX activity (78.0±30.3%), which resulted in an activity/antigen 
ratio decreased to half (0.50±0.15, Figure 3), suggesting a similarly increased amounts of both FIX 
molecules.









This article is protected by copyright. All rights reserved
In the frame of the GePKHIS study, the decay of infused FIX was determined in 29 HB patients, 
characterized for F9 genotypes. FIX variants corresponding to F9 mutations in HB patients 
(Figure 1B and Supporting Table 1) were recombinantly expressed, which confirmed their 
causative role and supported the PK analysis. The characteristic biphasic decay curves and the 
SSR values are reported in Supporting Figure 4, and the distribution of 2CP PK parameter values 
in Table 1.
The FIXag levels were directly correlated (Table 1) with Alpha HL and Beta HL, and inversely 
with CLD2, Cmax, and with K 1-2 and K 2-1, the latters two primary parameters modelling the 
flow between plasma and extravascular compartments (Supporting Figure 4). The correlation 
between FIXag levels and in vivo recovery, expressed as the ratio between maximum FIX activity 
and the FIX dose, was not significant (r=-0.289, p=0.128). On the other hand, the in vivo recovery 
has been reported to be quite variable even in the same patient on different occasions [52]. 
FIX antigen levels and PK parameters in HB patients grouped by mutation type 
The significant correlation between FIXag and Alpha HL (p=0.004; Table 1) prompted us to 
analyse the Alpha HL distribution in relation to missense variants. Individual FIXag and Alpha 
HL values and the overall relation (r2=0.386; Pearson r=0.622) are reported in Figure 4A.
FIXag levels (Table 2, first line) in patients (n=21) with missense mutations were higher than in 
patients (n=8) with null (nonsense, splicing and deletion) mutations (p=0.049). Patients with 
mutations at the activation sites (n=7) showed FIXag levels higher than those with null mutations 
(p=0.002) and than those patients  (n=12) with other missense mutations (“no activation sites”, 
n=14; p=0.001). 
The distribution of PK parameters according to the 2CP model was compared in patients with 
different mutation types (Table 2). Whereas differences between missense and null mutations were 
not detectable, missense changes at the activation site were associated with significantly lower K 
1-2, K 2-1 and CLD2 values, and longer Alpha HL, Beta HL and MRT than those observed in 
patients with null mutations, as well as in patients with other mutations (n=22, Table 2, last 
column). 
PK parameter values for Alpha HL, Beta HL and MRT in HB patients classified by mutation types 
are reported in Figure 4B. The distribution of PK values indicated high variability, either within 
patients with identical F9 mutations (p.R191C, p.R226Q, p.G236D; Figure 4B) or within a single 
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among null mutations, and by the p.N138H and p.A37D among missense changes not located at 
activation sites (Figure 4B).
Predictors of Alpha HL, Beta HL and MRT: FIX antigen levels and F9 genotypes 
The regression analysis of predictors of Alpha HL, Beta HL and MRT was conducted including 
the FIXag levels and the F9 mutation types, grouped either in missense and null, or activation site 
variants and other mutations (Table 3).  In the model including missense vs null mutations, FIXag 
values were independent predictors of Alpha HL (β coefficient 0.492, p=0.011), and as a trend of 
Beta HL (β coefficient 0.374, p=0.064). In the model including activation site variants vs other 
mutations, F9 genotypes were independent predictors of Alpha HL and MRT, and particularly of 
Beta HL (β coefficient 0.699, p=0.004). 
Discussion
Our data provide experimental evidence, based on in vivo and recombinant studies, to interpret the 
HB mutational patterns and phenotypes associated to the recurrent substitutions at the FIX 
activation sites.
Substitutions at R191 and R226 differentially affected residual antigen levels, with normal or 
increased protein levels associated to the R226 variants. High antigen values may be also 
associated to other catalytically inert variants as well as to missense mutations affecting the V227 
and V228 positions (Supporting Figure 2). Whereas the natural R226 substitutions do not permit 
the formation of a catalytically competent FIXa and cause severe HB, the benign R226K 
substitution, designed to mimic the positively charged WT arginine residue, permitted both 
efficient secretion and activation/activity, and accordingly is not comprised among HB mutations. 
Differently, most substitutions (L/A/G) affecting the R228 position cause moderate/mild HB 
(Supporting Figure 2). 
Multiple R191 variants are characterized by normal or modestly reduced antigen levels, and by a 
positive relation between activity and activity/antigen ratio. These observations suggest that the 
detrimental effects of substitutions at R191 on folding/secretion/scavenging processes [38,40,58], 
which all contribute to decrease antigen levels, decrease also activation and/or catalytic activity of 
the FIX R191 variants in a roughly proportional manner. In turn, these features shape the plasma 
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R191C>L>P>H substitutions. The R191H change results in the mildest and most frequent form 
(>100 HB patients), based on its normal FIXag levels and modest activity/antigen ratio. On the 
other hand, the benign R191Q/W/K changes, which predict FIX activity above the levels defining 
mild HB [59], are not reported neither in the HB nor in exome sequencing databases.
Overall, the recombinant experiments i) assist the interpretation of the wide and graded differences 
in plasma FIX activity and antigen levels observed in the numerous patients affected by mutations 
at the R191 position, and of the degree of the associated disease severity, and  ii) may predict the 
absence in the HB mutation database of several benign substitutions at the R191/R226 positions. 
A limitation of the recombinant approach is that antigen levels in vitro might not parallel those in 
vivo, caused by variable transfection efficiency or limited cellular capacity for post-translational 
modifications. However, each protein variant was expressed in six independent replicates in a 
cellular system widely used for its efficiency. Noticeably, the recombinant approach permits to 
detect FIX variants that are secreted, and thus could bind vascular and extravascular receptors, but 
might have increased clearance and thus show lower FIX antigen levels in plasma (i.e R191L).  
Further, the recombinant expression of FIX variants corresponding to HB causative mutations 
permitted us to refine the 2CP model PK analysis.  
Previous observations in HB patients led to hypothesize that the FIX CRM+ status may favourably  
influence [33,46] the PK of infused FIX or that dysfunctional endogenous FIX would impair 
prophylaxis in HB mouse models [35]. With potentially discrepant information as background, we 
investigated in HB patients the hypothesis that dysfunctional endogenous FIX, which circulates in 
variable amounts, might positively or negatively modulate the distribution of infused FIX. 
Prompted by the presence in our HB cohort of several patients affected by mutations at the 
activation sites causing retention of the activation peptide, previously reported to act as a plasma 
retention signal [31,32], we also explored whether the variably abundant antigen levels in these 
patients could further modulate the persistence of infused FIX in plasma. Worth noting, our study 
is the first report on the relation between FIX PK parameters and specific F9 mutations and well-
defined mutation groups.
The consistent correlation of primary and secondary PK parameters with dysfunctional 
endogenous FIX levels in HB patients supported the study of patients grouped by mutation types, 
which in turn dictate the concentration and features of dysfunctional molecules. Although FIXag 
levels were higher in patients with missense mutations than in those with null ones, their mean PK 
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levels associated to several missense changes (Figure 4A). The wide variability in antigen levels 
for the non-activation site missense changes could contribute to obscure mutation group 
differences in PK parameters.  Coherently, the grouping of missense and null mutations in linear 
regression analysis indicated FIXag levels, but not F9 genotypes, as significant predictors of PK 
parameters, particularly of Alpha HL. Differently, the activation site variants were associated with 
longer Alpha HL, Beta HL and MRT than null mutations. The MRT, a parameter that may 
influence patients’ treatment, was 80% longer (79.39 hrs, 95% CI 44.3-114.5) than in patients with 
null mutations (44.2 hrs, 95% CI, 30.8-57.5, p=0.031) or with other missense changes (45.9 hrs, 
95% CI 34.9-56.9, p=0.015). The regression analysis suggested activation site variants as 
independent predictors of several PK parameters, and particularly of Beta HL (β coefficient 0.699, 
p=0.004), which may be prolonged by the increasing proportion over time of the abundant 
endogenous FIX variants as compared to infused FIX. The very high endogenous/infused FIX 
ratio reached in the Beta elimination phase could magnify the effects of activation site variants, 
and the increasing competition for receptors may decrease both the forward and backward flow 
between central plasma and extravascular compartments [38–40] of infused FIX (Supporting 
Figure 5), thus prolonging its Alpha and Beta half-lives. The contribution to FIX PK of missense 
mutations, potentially produced also by other mutation types [60], may consist of quantitative 
components such as the residual FIXag levels, and in addition, for the R226 and R191 
substitutions, of qualitative components such as the retention of the activation peptide cleaved at 
only one site. It has been demonstrated that removal of the activation peptide from zymogen FIX 
results in exposure of a binding site for low-density lipoprotein receptor-related protein, which 
favors FIXa catabolism [58]. Whereas mutations at position R191 may modulate PK outcomes in 
the presence of intermediate FIXag levels, those at position R226 may influence PK parameters in 
the presence of high levels of the secreted FIX variants. It is tentative to speculate that in female 
carriers both levels of the FIX R226W variant and FIX WT would be increased, as suggested by 
the increased FIXag levels and the half-reduced activity/antigen ratio.
Although based on a limited number of patients and a small number of related female carriers, 
data suggest that mutations at the activation sites have pleiotropic effects in plasma by dictating in 
patients i) the residual FIX activity (only variants at R191), ii) the variably abundant FIXag, and 
by potentially modulating iii) the PK features of  the infused FIX and, in female carriers, iv) the 
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large differences among patients affected by identical F9 mutations, are expected to contribute the 
wide and elusive variability of PK outcomes in HB patients.
Our data support, in patients characterized for F9 mutations, the hypothesis [33] that the FIX 
CRM+ status might partially improve PK of FIX infused in HB patients, and that the activation 
peptide, retained in the activation site variants, may contribute to prolong the Beta phase of FIX 
distribution in plasma, as inferred in mouse models [31,32]. The relative impacts of FIXag levels 
versus retained activation peptide on FIX PK were indirectly disentangled by linear regression 
analysis that suggested activation site mutations as independent predictors, which warrants further 
studies. These F9-related features would permit to better estimate the improved pharmacokinetic 
profile of currently used and novel long-acting FIX molecules [61,62].
Conclusions
In vivo and recombinant results suggest that combination of  FIXag levels and type of 
dysfunctional molecules predicted in plasma by F9 mutations, particularly those at the activation 
sites, may exert pleiotropic effects on i) the endogenous FIX and thus HB patients’ phenotypes, as 
well as ii) infused FIX half-lives and thus MRT in substitutive treatment.
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Table 1. Correlation between FIX antigen and PK parameters of rFIX infused in HB patients.
Mean (95% CI)
FIX antigen (%) 43.70 (15.91-71.49)
Pearson’s correlation               
Primary PK parameters r p
K 1-2 (1/hrs) 0.14 (0.06-0.23) -0.461 0.012
K 2-1 (1/hrs) 0.26 (0.13-0.40) -0.469 0.010
V1 (dL/kg) 0.93 (0.78-1.08) 0.327 0.084
Secondary PK parameters
Alpha HL* (hrs) 5.11 (3.61-6.61) 0.516 0.004
AUC (U.h/dL) 1813 (1539-2086) -0.107 0.580
Beta HL (hrs) 43.24 (32.93-53.55) 0.397 0.033
CL (dL/hrs/kg) 0.031 (0.026-0.037) 0.024 0.900
CLD2 (dL/hrs/kg) 0.10 (0.04-0.16) -0.397 0.033
Cmax (IU/dL) 58.71 (48.73-68.69) -0.407 0.029
MRT (hrs) 53.50 (42.99-64.01) 0.311 0.101
V2 (dL/kg) 0.59 (0.39-0.79) 0.273 0.151
Vss (dL/kg) 1.52 (1.22-1.82) 0.340 0.072
r, Pearson’s coefficient. p, Pearson analysis. 
K 1-2, transfer rate from central (1) to peripheral (2) compartment; K 2-1, transfer rate from 
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alfa distribution half-life; AUC, area under the curve; Beta HL, beta elimination half-life; CL, 
clearance; CLD2, inter-compartment clearance; Cmax, at zero time extrapolated FVIII 
concentration; MRT, mean residence time; V2, volume of peripheral compartment; Vss, 
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Mean (95% CI) p Mean (95% CI) p Mean (95% CI) p Mean (95% CI) p# 
FIX antigen (%) 60.05 (23.48-96.62) 0.049 0.79 (-0.94-2.52) 0.002 163.3 (43.97-228.5) 0.001 21.95 (7.30-36.60)  <0.0001
PK parameters
K 1-2 (1/hrs) 0.17 (0.05-0.29) 0.825 0.09 (0.01-0.16) 0.004 0.03 (0.02-0.04) 0.028 0.23 (0.06-0.41) 0.016
K 2-1 (1/hrs) 0.30 (0.11-0.48) 0.664 0.17 (0.09-0.26) 0.001 0.04 (0.01-0.07) 0.002 0.42 (0.16-0.68) 0.001
V1 (dL/kg) 0.91 (0.78-1.04) 0.981 0.99 (0.46-1.52) 0.320 1.11 (0.85-1.38) 0.018 0.81 (0.68-0.94) 0.071
Alpha HL* (hrs) 5.70 (3.70-7.70) 0.196 3.56 (2.07-5.06) 0.001 9.53 (6.32-12.74) 0.002 3.79 (1.76-5.81) <0.0001
AUC (U.h/dL) 1857 (1526-2189) 0.633 1696 (1089-2303) 0.966 1757 (988-2527) 0.576 1907 (1503-2311) 0.717
Beta HL (hrs) 47.04 (33.18-60.90) 0.299 33.28 (23.73-42.82) 0.009 72.97 (38.15-107.8) 0.002 34.07 (25.33-42.82) <0.0001
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PK parameters in F9 mutation type groups were compared by t-test; the table includes four columns reporting p values, three of them flanked by the 
parameter values subjected to statistical evaluation. For p#, the comparison is made between missense mutations in the activation sites (n=7) and 
other mutations (the sum of null, missense no activation site, n=22, parameter values not reported in the table). *, normally distributed variable. PK 
parameters definition as in Table 1. 
CLD2 (dL/hrs/kg) 0.12 (0.04-0.20) 0.836 0.07 (0.04-0.10) 0.008 0.03 (0.02-0.04) 0.068 0.16 (0.04-0.28) 0.042
Cmax (IU/dL) 58.35 (45.84-70.85) 0.866 59.66 (39.29-80.05) 0.092 42.60 (30.41-54.73) 0.023 66.22 (49.09-83.35) 0.021
MRT (hrs) 57.06 (43.17-70.95) 0.297 44.16 (30.84-57.49) 0.031 79.39 (44.26-114.51) 0.015 45.90 (34.87-56.93) 0.005
V2 (dL/kg) 0.64 (0.37-0.92) 0.674 0.45 (0.31-0.59) 0.050 1.14 (0.35-1.92) 0.006 0.39 (0.28-0.50) 0.003
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Table 3. Linear regression models for predictors of the PK parameter variability 
ß-coefficient p Predictors
Alpha HL (hrs) 0.492 0.011 FIX antigen
-0.066 0.719 F9 genotypes - Missense vs null mutations
0.102 0.642 FIX antigen
0.569 0.015 F9 genotypes - Activation sites vs other mutations
Beta HL (hrs) 0.374 0.064 FIX antigen
-0.062 0.751 F9 genotypes - Missense vs null mutations
-0.111 0.623 FIX antigen
0.699 0.004 F9 genotypes - Activation sites vs other mutations
MRT (hrs) 0.274 0.182 FIX antigen
-0.099 0.623 F9 genotypes - Missense vs null mutations
-0.121 0.625 FIX antigen
0.594 0.023 F9 genotypes - Activation sites vs other mutations
Definition of PK parameters and mutation types as in Tables 1 and 2, respectively. The FIX 
antigen and PK parameter values in F9 mutation groups are reported in Table 2. Missense 
mutations (patients n= 21) vs null mutations (patients n= 8); mutations in the activation sites 
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FIGURE LEGENDS
Figure 1. Natural and designed amino acid substitutions at FIX activation sites.
A) Schematic representation of human coagulation FIX showing the pre- and pro-peptides (PP), 
and light and heavy chains (LC and HC, respectively). Haemophilia B (natural) variants affecting 
the R191 and R226 sites are reported above the FIX scheme (n, patient number in the EAHAD 
FIX variant Database https://f9-db.eahad.org/) [9], with the prevalent HB phenotypes associated 
with mutations on top.  Blue and red variants, patients also available in the GePKHIS study. 
Designed recombinant variants are indicated below the FIX scheme. Colour code: blue, red and 
black, natural variants; orange, designed variants. The alignment and conservation of residues in 
the two activation sites (red arrows) is also shown.
B) FIX variants available in the GePKHIS study. Missense (with amino acid changes not 
involving activation sites) and null (nonsense, splicing and deletion) variants are reported above 
and below the FIX scheme, respectively.
Figure 2. Characterization of FIX variants at the activation sites.
A) Activity (left panel) and antigen (right panel) levels of the 191 and 226 variants estimated in 
GePKHIS patients, reported in the international EAHAD FIX variant database (https://f9-
db.eahad.org/) [9] or upon recombinant expression. Reference for plasma or recombinant values 
were PNP or rFIX-WT, as appropriate.
B) Comparative expression of equivalent amino acid substitutions at 191 and 226 positions, after 
transient expression in HEK293 cells. The S411P variant (chymotrypsin numbering S195) was 
expressed as an additional control for inactive FIX with high antigen values.
C) Left panel. Western blotting analysis of the activation profile of natural (red) and designed 
(orange) recombinant 226 variants in the presence (+) or absence (-) of FXIa. Protein forms, 
resulting from FIX activation, as well as relative molecular weights (kDa), are indicated on left 
and right of the blot, respectively. Serial dilutions of rFIX-WT were loaded as control and 
reference. rFIX variants  with similar FIX antigen levels (226P/L/A/D/E/K, range 70%-100%) 
were tested after equal dilution (1:10) in PBS buffer, while those with antigen levels exceeding 
wild-type rFIX (226Q/W), prior to be diluted in PBS buffer, were first normalized to ~100% by 
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Zym, zymogen FIX; FXIa, activated factor XI.
Right panel. FIX antigen and activity levels, as well as activity/antigen ratio, of the designed 226K 
variant. 
D) Comparative analysis of activity and antigen levels of FIX variants bearing natural missense 
changes found in HB patients (p, red squares; left panel) and after recombinant expression (r, blue 
circles; right panel).
E) Relation between mean activity levels and activity/antigen ratio of FIX variants bearing natural 
(blue circles) or designed (orange circles) amino acid substitutions.
Inset, Analysis of the relation with the 191K variant included.
Results, indicated as % of reference, are reported as mean±SEM (panels A, patients bar, and E) or 
mean±SD of n=6 replicates (panels A, recombinant bar, B and C).
*, p<0.05; **, p<0.01; ***, p<0.001 ****, p<0.0001.
Figure 3. Analysis of female carriers of the p.R226W variant.
Plasma FIX antigen and activity levels, as well as activity/antigen ratio, estimated in female 
carriers (n=3) of the p.R226W variant. Results are reported as mean±SEM. *, p<0.05.
Figure 4. FIX PK parameters, FIX antigen and F9 genotypes.
A) Alpha HL parameter, F9 genotypes and FIX antigen levels. Relation between mean antigen 
levels of expressed FIX missense variants of the HB cohort and Alpha HL parameter. Alpha HL of 
the R191C (n=3 patients), R226Q (n=3) and G236D (n=2) variants is reported as mean of PK 
values from each patient.
B) Alpha HL, Beta HL and MRT and F9 genotypes. Comparative plot of selected PK parameters 
(Alpha HL, upper panel; Beta HL, middle panel; MRT, lower panel) among FIX variants 
categorized by three mutation groups: null (nonsense, splicing, deletion), missense variants 
affecting (act. sites) or not (no act. sites) the FIX R191 or R226 activation sites.
Circles, activation site variants (blue, R191C; red, R226Q/W); grey squares, nonsense variants; 
grey triangles, no activation site variants.
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